New Round Of Drug Maker Consolidation Expected In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's drug-making industry anticipates a new spurt of consolidation moves as previous capital investments cause companies charge off increasing amounts of depreciation. The generics part of the industry in Japan is estimated to be using only a little more than half its production capacity as a result of firms expanding capacity ahead of expected market growth. That situation is expected to make small and midsize firms exposed as targets for acquisition, particularly in the eyes of Indian drug makers. But large Japanese firms also are beginning to buy their smaller cousins. (Click here for more - a subscription may be required
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.